The AMP SCZ initiative focuses on understanding schizophrenia through a comprehensive study involving over 2,617 participants. Participants will be assessed for up to two years using various measures including clinical assessments, neuroimaging, and biomarkers. The project seeks to establish reliable biomarkers and clinical tools to aid in clinical trials for at-risk individuals. A reissue of the Data Processing Analysis Coordination Center is essential to maintain data processing quality and ensure timely analysis, ultimately benefiting research and treatment strategies for schizophrenia.
The AMP SCZ initiative is leveraging a large investment from NIMH and public-private partners to conduct the most comprehensive, longitudinal study in individuals at risk for schizophrenia.
Over 2,617 study participants have been recruited into the study. Study participants will be assessed longitudinally for up to 24 months.
A reissue of the Data Processing Analysis Coordination Center is needed to ensure continuity of data processing, real-time quality assurance/quality control pipelines, and completion of the primary analyses of the full data set.
Valid biomarkers, clinical assessment tools, and algorithms would have a significant positive impact on clinical trials of novel interventions for this relatively understudied population.
Collection
[
|
...
]